SEC62 and colorectal carcinoma: To solidify the result that MAPK/JNK signalling could be triggered by Sec62 activation in CRC, we measured whether activating or suppressing MAPK/JNK signalling with JNK agonist (Anisomycin) or inhibitor (SP600125) would affect Sec62‐mediated CRC metastatic capability.